Kane Biotech Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Huizinga
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 290-100 Innovation Drive Winnipeg MB Canada R3T 6G2
- IPO Date
- Aug 7, 2007
- CIK
- 0001464368
- Website
- kanebiotech.com
- Similar Companies
- Business
- Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) is a biotechnology company engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its offerings using proprietary coactiv+ technology, a biofilm-destabilizing formula providing continuous activity, and DispersinB technology, a naturally occurring enzyme that cleaves bacterial surface polysaccharide PNAG for applications in wound and otic treatments; its wound care portfolio includes revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Wound Rinse, alongside coactiv+ Antimicrobial Surgical Hydrogel, with development-stage products such as DispersinB Hydrogel, DispersinB Acne Cleanser, and coactiv+ Antimicrobial Surgical Hydrogel targeting surgical/acute wounds and chronic conditions; additional segments encompass DermaKB shampoos, shampoo bars, and scalp detoxifiers for dermatology; bluestem animal health oral care products; and, following a November 2024 agreement, integration of FB Dermatology's portfolio featuring LumiHeal for chronic wounds and surgical scar reduction via Fluorescence Biomodulation, Kleresca for skin rejuvenation, acne, and rosacea, and Lumixa for photobiomodulation-based skin regeneration. Founded in 2001 and headquartered at 290-100 Innovation Drive, Winnipeg, Manitoba, Canada, Kane Biotech operates across human health, dermatology, wound care, and animal health segments, targeting healthcare providers, consumers, and veterinary markets in North America, Europe, Australia, New Zealand, and beyond. Recent developments include a binding term sheet announced November 12, 2024, to acquire FB Dermatology for a combination of cash, shares, and warrants to bolster wound care and dermatology capabilities with global commercial synergies such as U.S. launches of LumiHeal paired with coactiv+ products and accelerated revyve distribution; a $3 million private placement offering in December 2024 and a prior $2.2 million financial restructuring via private placement and insider loan conversion; termination of the ProgenaCare distribution agreement and election of three new board directors; completion of U.S. FDA 510(k) submission for revyve Antimicrobial Wound Cleanser in September 2025 alongside enrollment in case series studies for revyve Gel and Spray; presentations of preclinical data showing up to 100% reduction in key enzymes and clinical case studies at major wound care conferences including SAWC Fall and Diabetic Foot events; and a strategic shift narrowing focus to four core coactiv+-based wound products while implementing cost reductions amid Q3 2025 financial reporting.
Company News
Kane Launches New Corporate Brand and Redesigned Website
Kane Biotech Announces $250,000 Insider Loan
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Transcript
Kane Biotech to Host Commercial Update Webcast on September 16
Kane Biotech Announces Second Quarter 2026 Financial Results
Kane Biotech Announces Engagement of DNA Advisors
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Kane Biotech Announces Grant of Stock Options
Kane Biotech Announces First Quarter 2026 Financial Results
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
Kane Biotech Announces New Private Placement Offering
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
Kane Biotech Expands Commercial Activities in the United States
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser